| Literature DB >> 34326955 |
Shuai Wang1, Hui Yong1, Xiao-Dong He2.
Abstract
Type 2 diabetes mellitus (T2DM) is a burdensome global disease. In-depth understanding of its mechanism will help to optimize diagnosis and treatment, which reduces the burden. Multi-omics research has unparalleled advantages in contributing to the overall understanding of the mechanism of this chronic metabolic disease. In the past two decades, the study of multi-omics on T2DM-related intestinal flora perturbation and plasma dyslipidemia has shown tremendous potential and is expected to achieve major breakthroughs. The regulation of intestinal flora in diabetic patients has been confirmed by multiple studies. The use of metagenomics, 16S RNA sequencing, and metabolomics has comprehensively identified the overall changes in the intestinal flora and the metabolic disturbances that could directly or indirectly participate in the intestinal flora-host interactions. Lipidomics combined with other "omics" has characterized lipid metabolism disorders in T2DM. The combined application and cross-validation of multi-omics can screen for dysregulation in T2DM, which will provide immense opportunities to understand the mechanisms behind T2DM. ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.Entities:
Keywords: Dyslipidemias; Gastrointestinal microbiome; Intestinal flora; Lipid metabolism disorders; Metabolomics; Type 2 diabetes mellitus
Year: 2021 PMID: 34326955 PMCID: PMC8311486 DOI: 10.4239/wjd.v12.i7.1070
Source DB: PubMed Journal: World J Diabetes ISSN: 1948-9358
Figure 1Multi-omics verification of the mechanism of type 2 diabetes mellitus. A: Schematic diagram of multi-omics verification; B: Conceptual diagram of the Zucker diabetic fatty rat modeling process; C: Body weight (left) and blood sugar (right) before and after basic diet feeding in B; D: Fecal 16S rRNA sequencing biomarkers; E: Genomic functions of the disturbed intestinal flora; F: Overview of the complete metabolism in the two biological system; G: Protein-protein interaction network of plasma differentially expressed proteins (DEPs); H: Functional enrichment of DEPs; I: Visualization of G and H. The cross-validation of intestinal flora and the plasma proteome further emphasizes that oxidative stress, insulin resistance, energy intake and consumption imbalances, and lipid metabolism disorders play an important part in the occurrence of type 2 diabetes mellitus (T2DM). Dyslipidemia may be a major hub for the in vivo and in vitro changes in T2DM (unpublished data). The data used in the figure are our published and public data in open access journals, which are displayed after further analysis. C and G: Citation: Wang S, Lu Z, Wang Y, Zhang T, He X. Metalloproteins and apolipoprotein C: candidate plasma biomarkers of T2DM screened by comparative proteomics and lipidomics in ZDF rats. Nutr Metab (Lond) 2020; 17: 66. Copyright ©The Author(s) 2020. Published by Springer Nature[6]. T: Zucker leptin receptor gene-deficient rats (fa/fa) treated by Purina #5008 for 3 wk; C: Basic diet-fed litter mate wild-type controls (fa/+); DEPs: Differentially expressed proteins; T2DM: Type 2 diabetes mellitus.
Intestinal flora-related metabolites and their host interaction mechanism
|
|
|
| Bile acids | Promotes fat absorption; serves as signaling molecule [acts with G-protein-coupled bile acid receptor 1 (Gpbar1, TGR5) and the bile acid receptor FXR]; limits the autoimmune response |
| SCFA | |
| Acetate and butyrate | Acts as histone deacetylase inhibitors; ameliorates inflammation |
| Propionate | Participates in carbohydrate esterification |
| Valeric | Provides calories; affects inflammation; enteroendocrine regulation through G-protein-coupled receptors ( |
| Indole | Promotes the function of the intestinal cell epithelial barrier; enhances the secretion of glucagon-like peptide-1 (GLP-1) |
| Endotoxins (LPS) | Induces inflammation; limits the autoimmune response |
| H2S | Destroys the intestinal barrier function |
| TMA | Interferes with metabolism |
Gpbar1 (TGR5): G-protein-coupled bile acid receptor 1; FXR: Farnesoid X receptor; SCFA: Short-chain fatty acid; GPR: G-protein-coupled receptors; GLP-1: Glucagon-like peptide-1; LPS: Lipopolysaccharide; H2S: Hydrogen sulfide; TMA: Trimethylamine.